Immix Biopharma reports 89% complete response rate in interim Phase 2 NXC-201 data for AL amyloidosis, plans BLA submission mid-2027

Immix Biopharma reported an 89% complete response rate in interim Phase 2 data for NXC-201 in AL amyloidosis, and said it plans to submit a BLA in mid-2027.

Detected & updated continuously · Source: Nebula